JP2006512396A - 免疫寛容を誘導および維持する方法 - Google Patents

免疫寛容を誘導および維持する方法 Download PDF

Info

Publication number
JP2006512396A
JP2006512396A JP2004565643A JP2004565643A JP2006512396A JP 2006512396 A JP2006512396 A JP 2006512396A JP 2004565643 A JP2004565643 A JP 2004565643A JP 2004565643 A JP2004565643 A JP 2004565643A JP 2006512396 A JP2006512396 A JP 2006512396A
Authority
JP
Japan
Prior art keywords
cells
antagonist
treatment
cell
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2004565643A
Other languages
English (en)
Japanese (ja)
Other versions
JP2006512396A5 (es
Inventor
ジャネット リバーシッジ，
アンドリュー ディック，
ジョナサン セジウィック，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme Corp
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of JP2006512396A publication Critical patent/JP2006512396A/ja
Publication of JP2006512396A5 publication Critical patent/JP2006512396A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Communicable Diseases (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Rehabilitation Therapy (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
JP2004565643A 2002-12-27 2003-12-18 免疫寛容を誘導および維持する方法 Pending JP2006512396A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US43673902P 2002-12-27 2002-12-27
PCT/US2003/040986 WO2004060295A2 (en) 2002-12-27 2003-12-18 Methods of inducing and maintaining immune tolerance

Publications (2)

Publication Number Publication Date
JP2006512396A true JP2006512396A (ja) 2006-04-13
JP2006512396A5 JP2006512396A5 (es) 2007-01-25

Family

ID=32713084

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2004565643A Pending JP2006512396A (ja) 2002-12-27 2003-12-18 免疫寛容を誘導および維持する方法

Country Status (7)

Country Link
US (2) US20040213783A1 (es)
EP (1) EP1585545A4 (es)
JP (1) JP2006512396A (es)
AU (1) AU2003299823A1 (es)
CA (1) CA2511513A1 (es)
MX (1) MXPA05006978A (es)
WO (1) WO2004060295A2 (es)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010534242A (ja) * 2007-07-25 2010-11-04 アレクシオン ファーマシューティカルズ， インコーポレイテッド 自己免疫疾患を治療するための方法および組成物

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020192215A1 (en) * 1999-04-13 2002-12-19 Schering Corporation, A New Jersey Corporation Novel uses of mammalian OX2 protein and related reagents
KR101018134B1 (ko) * 1999-05-13 2011-02-25 쉐링 코포레이션 Ｏｘ2 수용체 동족체
US9249229B2 (en) 2000-12-08 2016-02-02 Alexion Pharmaceuticals, Inc. Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof
US20060057651A1 (en) 2000-12-08 2006-03-16 Bowdish Katherine S Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof
US7408041B2 (en) 2000-12-08 2008-08-05 Alexion Pharmaceuticals, Inc. Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof
EP1341902A2 (en) 2000-12-08 2003-09-10 Alexion Pharmaceuticals, Inc. Chronic lymphocytic leukemia cell line and its use for producing an antibody
CA2462883A1 (en) * 2001-10-12 2003-04-17 Schering Corporation Use of bispecific antibodies to regulate immune responses
DK2463305T3 (en) 2006-01-12 2016-08-29 Alexion Pharma Inc Antibodies to OX-2 / CD200 and uses thereof
DK2037967T3 (en) * 2006-06-16 2017-03-13 Univ Pennsylvania PROSTAGLANDIN-D2 RECEPTOR ANTAGONISTS FOR TREATMENT OF ANDROGENETIC ALOPECI
WO2009004339A2 (en) * 2007-07-03 2009-01-08 Imperial Innovations Limited Compositions and methods relating to manipulation of the myeloid immune compartment during respiratory infection
BRPI0814644A2 (pt) 2007-07-25 2015-01-27 Alexion Pharma Inc Anticorpos para cd200 e usos destes na inibição de respostas imunes.
JP6012473B2 (ja) 2010-01-11 2016-10-25 アレクシオン ファーマシューティカルズ， インコーポレイテッド 抗ｃｄ２００抗体を用いたヒトの処置における免疫調節効果のバイオマーカー
NZ601580A (en) 2010-02-11 2014-11-28 Alexion Pharma Inc Therapeutic methods using anti-cd200 antibodies
US9447187B2 (en) 2011-02-03 2016-09-20 Alexion Pharmaceuticals, Inc. Use of an anti-CD200 antibody for prolonging the survival of allografts
EP3626739A1 (en) 2011-06-24 2020-03-25 Stephen D. Gillies Light chain immunoglobulin fusion proteins and methods of use thereof
KR102379464B1 (ko) 2016-06-20 2022-03-29 키맵 리미티드 항-pd-l1 항체
WO2019067499A1 (en) 2017-09-27 2019-04-04 Alexion Pharmaceuticals, Inc. BIOMARKER SIGNATURE FOR PREDICTING A TUMOR RESPONSE TO ANTI-CD200 THERAPY
US11802154B2 (en) 2017-12-20 2023-10-31 Alexion Pharmaceuticals, Inc. Humanized anti-CD200 antibodies and uses thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6955811B2 (en) * 1997-11-07 2005-10-18 Trillium Therapeutics Inc. Methods of inhibiting immune response suppression by administering antibodies to OX-2
CA2308765C (en) * 1997-11-07 2010-10-12 Transplantation Technologies Inc. The use of an ox-2 protein or nucleic acid in immunomodulation
US20020192215A1 (en) * 1999-04-13 2002-12-19 Schering Corporation, A New Jersey Corporation Novel uses of mammalian OX2 protein and related reagents
KR101018134B1 (ko) * 1999-05-13 2011-02-25 쉐링 코포레이션 Ｏｘ2 수용체 동족체
AU2001278338A1 (en) * 2000-08-03 2002-02-18 David A Clark Methods and compositions for modulating tumor growth
CA2448668A1 (en) * 2001-05-24 2002-11-28 Trillium Therapeutics Inc. Modulation of cd200 receptors
DK1482973T3 (da) * 2002-03-15 2009-12-07 Schering Corp Fremgangsmåde til modulering af CD200-receptorer
WO2003103709A2 (en) * 2002-06-07 2003-12-18 Trillium Therapeutics Inc. Modulation of bone development

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010534242A (ja) * 2007-07-25 2010-11-04 アレクシオン ファーマシューティカルズ， インコーポレイテッド 自己免疫疾患を治療するための方法および組成物

Also Published As

Publication number Publication date
EP1585545A4 (en) 2006-04-12
CA2511513A1 (en) 2004-07-22
MXPA05006978A (es) 2005-08-16
US20040213783A1 (en) 2004-10-28
US20070065438A1 (en) 2007-03-22
AU2003299823A8 (en) 2004-07-29
WO2004060295A3 (en) 2004-09-30
WO2004060295A2 (en) 2004-07-22
EP1585545A2 (en) 2005-10-19
AU2003299823A1 (en) 2004-07-29

Similar Documents

Publication Publication Date Title
US20240210393A1 (en) Detection and treatment of autoimmune disorders
JP6494434B2 (ja) プログラム細胞死１（ｐｄ−１）経路を阻害することによる持続感染および癌の処置のための方法および組成物
JP2006512396A (ja) 免疫寛容を誘導および維持する方法
JP5623747B2 (ja) 感染症および腫瘍を処置するための組成物および方法
JP2011509676A (ja) ヒトＴｈ１７細胞の選択的分化、同定および調節
JP2006514654A (ja) 線維細胞への分化の検出方法、線維症を抑制する組成物および方法
WO2003057243A1 (en) Diagnosis and therapy of antibody-mediated inflammatory autoimmune disorders
EP2950095B1 (en) Cell-based assay and screening methods for modulators of p75NTR signaling
BR112020013531A2 (pt) Uso de anticorpo anti-il-6, por exemplo, clazakizumab para dessensibilização de receptores de transplante de órgãos sólidos e/ou para prevenir, estabilizar ou reduzir rejeição mediada por anticorpos (abmr)
JP2007534775A (ja) 脈管の疾患を処置するための方法
CN112451661A (zh) α-烯醇化酶特异性抗体及其在免疫疾病治疗中的使用方法
Buchele et al. Th17 cell-mediated colitis is positively regulated by interferon regulatory factor 4 in a T cell-extrinsic manner
Nicholson et al. Effects of ICOS+ T cell depletion via afucosylated monoclonal antibody MEDI-570 on pregnant cynomolgus monkeys and the developing offspring
WO2010068923A2 (en) Agents that selectively inhibit cd25 on dendritic cells or t cells and their use
AU4848899A (en) Methods and agents for the detection and modulation of cellular immunity to immune privileged antigens
WO2021085295A1 (ja) 免疫応答抑制剤
Duizendstra Rejection and Tolerance after Liver Transplantation
Eckf et al. Effects of ICOS+ T cell depletion via afucosylated monoclonal antibody MEDI-570 on pregnant cynomolgus monkeys and the developing offspring.
US20150362508A1 (en) Effector t cell rsistance
Zhang et al. PREVENTION OF OBLITERATIVE BRONCHIOLITIS BY JAK 3 INHIBITION WITH CP-690,550 IS ACCOMPANIED BY A DISTINCT GROWTH FACTOR GENE EXPRESSION PROFILE.
Wajed et al. 19. Could it be Magic
BACHER et al. K. 1 Role of microglia and macrophages in a defined demyelinated lesion in the corpus callosum of adult Sprague-Dawley rats
Ushigome et al. GITR activation in donor specific transfusion accelerates allograft rejection

Legal Events

Date Code Title Description
A521 Written amendment

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20061128

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20061128

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20100219

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20100708